A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors
Completed · Phase 1
Conditions studied: Advanced Cancer
In brief
Part I will evaluate the pharmacokinetic profile and safety of KTN3379 over several doses with the objective of defining a Phase 2 dose in patients with advanced malignancies. Part II will evaluate the pharmacokinetic profile and safety of KTN3379 in combination with other targeted agents and obtain preliminary evidence of anti tumor activity in specific types of cancer. Patients will continue receiving KTN3379 alone or in combination until disease progression or toxicity that necessitates discontinuation (whichever comes first).
Key facts
- Study ID
- NCT02014909
- Run by
- Celldex Therapeutics
- People needed
- 64
- Starts
- 2014-01-01
- Expected to finish
- 2017-06-05
- Last updated by the study team
- 2017-07-24
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Sarah Cannon Research Institute — Denver, Colorado, United States
- Yale Cancer Center — New Haven, Connecticut, United States
- Barbara Ann Karmanos Cancer Institute — Detroit, Michigan, United States
- University of Pennsylvania Perelman School of Medicine — Philadelphia, Pennsylvania, United States
- Sarah Cannon Research Institute — Nashville, Tennessee, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.